LEXICON PHARMACEUTICALS, INC. Revenue, Net (Deprecated 2018-01-31)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Revenue, Net (Deprecated 2018-01-31) of $33.05 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Income Statement › Revenue
us-gaap:SalesRevenueNet · last filed 2018-03-01
- LEXICON PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $33.05M, a 43.45% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $26.94M, a 2.80% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $12.05M, a 40.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $18.29M, a 46.41% increase year-over-year.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $33.05M 10-K · filed 2018-03-01 | $59.99M derived: sum of 2 quarters · filed 2018-03-01 | $72.04M derived: sum of 3 quarters · filed 2018-03-01 | $90.33M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-09-30 | $26.94M 10-K · filed 2018-03-01 | $38.99M derived: sum of 2 quarters · filed 2018-03-01 | $57.29M derived: sum of 3 quarters · filed 2018-03-01 | $80.33M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-06-30 | $12.05M 10-K · filed 2018-03-01 | $30.35M derived: sum of 2 quarters · filed 2018-03-01 | $53.38M derived: sum of 3 quarters · filed 2018-03-01 | $81.10M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-03-31 | $18.29M 10-K · filed 2018-03-01 | $41.33M derived: sum of 2 quarters · filed 2018-03-01 | $69.05M derived: sum of 3 quarters · filed 2018-03-01 | $89.14M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-12-31 | $23.04M 10-K · filed 2018-03-01 | $50.75M derived: sum of 2 quarters · filed 2018-03-01 | $70.84M derived: sum of 3 quarters · filed 2018-03-01 | $83.34M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-09-30 | $27.72M 10-K · filed 2018-03-01 | $47.81M derived: sum of 2 quarters · filed 2018-03-01 | $60.30M derived: sum of 3 quarters · filed 2018-03-01 | |
| 2016-06-30 | $20.09M 10-K · filed 2018-03-01 | $32.58M derived: sum of 2 quarters · filed 2018-03-01 | ||
| 2016-03-31 | $12.49M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |